scholarly journals Ankylosing spondylitis and inflammatory bowel disease. I. Prevalence of inflammatory bowel disease in patients suffering from ankylosing spondylitis.

1978 ◽  
Vol 37 (1) ◽  
pp. 30-32 ◽  
Author(s):  
S G Meuwissen ◽  
B J Dekker-Saeys ◽  
D Agenant ◽  
G N Tytgat
Keyword(s):  
Inflammatory Bowel Disease ◽  
Ankylosing Spondylitis ◽  
Bowel Disease ◽  
Inflammatory Bowel

scholarly journals AB0702 THE FREQUENCY OF INFLAMMATORY BOWEL DISEASES IN PATIENTS WITH ANKYLOSING SPONDYLITIS

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 1647.2-1647
Author(s):  
G. Lukina ◽  
P. Kulakova ◽  
N. Savenkova ◽  
E. Volnukhin ◽  
A. Kovshik ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Longitudinal Study ◽  
Ankylosing Spondylitis ◽  
Disease Activity ◽  
Bowel Disease ◽  
Rapid Test ◽  
Neutrophil Infiltration ◽  
Fecal Calprotectin ◽  
High Disease Activity ◽  
Inflammatory Bowel

Background:Аnkylosing Spondylitis (AS) is closely associated with inflammatory bowel disease (IBD). About 6-46% of patients with IBD have various lesions of the musculoskeletal system [1]. 5-10% of patients with spondylarthritis (SpA) eventually develop IBD, with Crohn’s disease (CD) being more common than Ulcerative colitis (UC) [2]. Determining the level of fecal calprotectin (FC) is a study that allows to diagnose IBD. The concentration of FC directly depends on the neutrophil infiltration of the intestinal mucosa and has a direct connection with the activity of the inflammatory process [3]. It is known that level of FC increases in 2/3 of patients with AS and is closely related to parameters reflecting higher disease activity [4].Objectives:The aim of this study was to evaluate the frequency of IBD in patients with AS using an assessment of FC level.Methods:In the analysis were included 40 patients with AS, fulfilling the modified New York criteria, among them man -26 (65%), woman -14 (35%), mean age of patients was 41.2 ±10.5, mean disease duration - 13±8.8 years. All patients were examined with ESR, CRP, esophagogastroduodenoscopy, colonoscopy and quantitative analysis of the fecal calprotectin levels using the method of lateral immunochromatography with the BUHLMANN Quantum Blue rapid test. Standart range: 100-1800 µg /g.Results:All patients had a high disease activity, mean BASDAI was 5.2 ± 1.7, mean ASDAS CRP 3.8 ± 1.1. 35 patients (87.5 %) had FC level more than 100 µg / g, the remaining 5 patients (12.5%) less than 100 µg /g. 12 patients (30 %) had FC level more than 1,800 µg / g, 23 (57.5 %) from 101 µg / g to 1800 µg / g. All patients with FC levels more than 100 µg / g showed an increase CRP (mean 28.4 mg / l) and ESR (mean 36.3 mm\h) levels. IBD were diagnosed in 9 cases (22.5%): 5 patients (12.5 %) with CD and 4 patients (10 %) - UC, in the remaining cases (77.5%) was no intestinal pathology.Conclusion:The results showed high frequency of IBD in patients with AS. Patients with high FC levels (more than 100 μg/g) had high disease activity (AS). In most cases, inflammatory bowel disease were diagnosed in patients with FC levels more than 100 µg/g.References:[1] Bernstein CN, Blanchard JF, Rawsthorne P, Yu N. The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. Am J Gastroenterol. 2001 Apr;96(4):1116-22.[2] Klingberg, E., Strid, H., Stahl, A.et al. A longitudinal study of fecal calprotectin and the development of inflammatory bowel disease in ankylosing spondylitis. A longitudinal study of fecal calprotectin and the development of inflammatory bowel disease in ankylosing spondylitis. Arthritis Res Ther 2017. 19(1):21[3] Cypers H, Varkas G, Beeckman S, et al. Elevated calprotectin levels reveal bowel inflammation in spondyloarthritis. Annals of the Rheumatic Diseases. 2016. 75:1357-1362[4] Arzu Duran, Senol Kobak, Nazime Sen, et al. Fecal calprotectin is associated with disease activity in patients with ankylosing spondylitis. Bosnian Journal of Basic Medical Sciences. 2016. 16 (1):71-4Disclosure of Interests:Galina Lukina Speakers bureau: Novartis, Pfizer, UCB, Abbvie, Biocad, MSD, Roche, Polina Kulakova: None declared, Nadezhda Savenkova: None declared, Evgeniy Volnukhin: None declared, Anton Kovshik: None declared, Elena Alexandrova: None declared, Alexandr Novikov: None declared

scholarly journals Lipocalin 2 links inflammation and ankylosis in the clinical overlap of inflammatory bowel disease (IBD) and ankylosing spondylitis (AS)

2020 ◽  
Vol 22 (1) ◽  
Author(s):  
Aifeng Lin ◽  
Robert D. Inman ◽  
Catherine J. Streutker ◽  
Zhenbo Zhang ◽  
Kenneth P. H. Pritzker ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Ankylosing Spondylitis ◽  
Bowel Disease ◽  
Lipocalin 2 ◽  
Inflammatory Bowel

scholarly journals Sulphasalazine-Induced Pseudomembranous Colitis

1991 ◽  
Vol 5 (5) ◽  
pp. 167-170 ◽  
Author(s):  
Hugh J Freeman ◽  
Urs P Steinbrecher ◽  
WC Peter Kwan ◽  
Stephanie Ensworth
Keyword(s):  
Inflammatory Bowel Disease ◽  
Abdominal Pain ◽  
Ankylosing Spondylitis ◽  
Clostridium Difficile ◽  
Bowel Disease ◽  
Pseudomembranous Colitis ◽  
Flexible Sigmoidoscopy ◽  
Frequent Use ◽  
Toxin Assay ◽  
Inflammatory Bowel

An 18-year-old female with ankylosing spondylitis developed fever, abdominal pain and diarrhea on two occasions after starting sulphasalazine therapy. Flexible sigmoidoscopy revealed pseudomembranous colitis; fecal cultures were positive forClostridium difficile; andC difficiletoxin assay was positive. Despite the frequent use of sulphasalazine in the management of inflammatory bowel disease, this complication has been apparently rare. Clinicians should be wary of the onset of diarrhea in patients receiving sulphasalazine, whether for inflammatory bowel disease or other conditions.

scholarly journals Gender differences among patients with primary ankylosing spondylitis and spondylitis associated with psoriasis and inflammatory bowel disease in an iberoamerican spondyloarthritis cohort

Medicine ◽  
2016 ◽  
Vol 95 (51) ◽  
pp. e5652 ◽  
Author(s):  
Margarita Landi ◽  
Hernán Maldonado-Ficco ◽  
Rodolfo Perez-Alamino ◽  
José A. Maldonado-Cocco ◽  
Gustavo Citera ◽  
...  
Keyword(s):  
Gender Differences ◽  
Inflammatory Bowel Disease ◽  
Ankylosing Spondylitis ◽  
Bowel Disease ◽  
Inflammatory Bowel

Golimumab May Induce Exacerbation of Inflammatory Bowel Disease When It Is Used for the Treatment of Ankylosing Spondylitis

2014 ◽  
Vol 21 (1) ◽  
pp. e26-e27 ◽  
Author(s):  
Muhammad Z. Bawany ◽  
Ehsan Rafiq ◽  
Raja Thotakura ◽  
Roberta Lay ◽  
Ann L. Silverman ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Ankylosing Spondylitis ◽  
Bowel Disease ◽  
Inflammatory Bowel

A common genetic background for inflammatory bowel disease and ankylosing spondylitis: A genealogic study in Iceland

2007 ◽  
Vol 56 (8) ◽  
pp. 2633-2639 ◽  
Author(s):  
Bjarni Thjodleifsson ◽  
árni J. Geirsson ◽  
Sigurdur Björnsson ◽  
Ingvar Bjarnason
Keyword(s):  
Inflammatory Bowel Disease ◽  
Ankylosing Spondylitis ◽  
Bowel Disease ◽  
Genetic Background ◽  
Inflammatory Bowel

Complete Reversal of Nephrotic Syndrome Secondary to Amyloidosis with Use of Infliximab in a Patient with Inflammatory Bowel Disease and Ankylosing Spondylitis

Renal Failure ◽  
2011 ◽  
Vol 33 (5) ◽  
pp. 531-533 ◽  
Author(s):  
Mehmet Fatih Akdoğan ◽  
Murat Gücün ◽  
Nazım Denizli ◽  
Murat Güney ◽  
İbrahim Akdag ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Nephrotic Syndrome ◽  
Ankylosing Spondylitis ◽  
Bowel Disease ◽  
Complete Reversal ◽  
Inflammatory Bowel
Sign in / Sign up

Export Citation Format

Share Document